AGIO analyst estimates

Agios Pharmaceuticals (AGIO) analyst ratings, the average price target and its range, and every firm's latest call.

AGIO analyst ratings and price targets

DateFirmCallTarget
Oct 7, 2026Truist FinancialAgios Pharmaceuticals price target lowered to $37 from $39 at Truist$37.00
Jul 30, 2026H.C. WainwrightAgios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright$55.00
Jul 21, 2026H.C. WainwrightAgios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright$52.00
Jul 7, 2026RBC CapitalAgios Pharmaceuticals price target raised to $32 from $28 at RBC Capital$32.00
Jul 7, 2026Truist FinancialAgios Pharmaceuticals price target raised to $41 from $36 at Truist$41.00
Jun 15, 2026H.C. WainwrightAgios Pharma (AGIO) PT Raised to $54 at H.C. Wainwright$54.00
Apr 30, 2026Truist FinancialAgios Pharmaceuticals price target lowered to $36 from $39 at Truist$36.00
Apr 20, 2026H.C. WainwrightH.C. Wainwright cuts Agios target on smaller market post Novo data$50.00
Feb 12, 2026Truist FinancialAgios Pharma (AGIO) PT Raised to $39 at Truist Securities$39.00
Dec 26, 2025Leerink PartnersAgios Pharmaceuticals price target raised to $40 from $34 at Leerink$40.00
Dec 24, 2025Truist FinancialAgios Pharmaceuticals price target raised to $38 from $32 at Truist$38.00
Dec 24, 2025H.C. WainwrightAgios Pharmaceuticals price target raised to $62 from $48 at H.C. Wainwright$62.00
Nov 24, 2025Truist FinancialAgios Pharmaceuticals initiated with a Buy at Truist$32.00
Nov 20, 2025Leerink PartnersLeerink upgrades Agios to Outperform after 51% pullback$34.00
Nov 20, 2025Goldman SachsAgios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs$25.00

Updated 2026-11-02 23:59 UTC